Opdivo (nivolumab) for adrenocortical carcinoma – pro
Nivolumab as a single drug has only recently been preliminarily studied with eh conclusion by the main authors, L. Cavalcante that it is well tolerated. This was a study fo single agent nivolumab, not in combination with chemotherapy. Efficacy data had not been published yet and it continues in a clinical trial. NMovolumab has both theoretical and cas=reprot evidence for activity but it remains to be proven, especially in combination with chemotherapy.
Ludimila Cavalcante, Benedito A. Carneiro, Ricardo Lima Barros Costa, Young Kwang Chae, Alfred Rademaker, and Francis J. Giles, Preliminary results from a phase II study of nivolumab for patients with metastatic adrenocortical carcinoma (ACC). Journal of Clinical Oncology 2017 35:7_suppl, 96-96
Costa R, Carneiro BA, Tavora F, et al. The challenge of developmental therapeutics for adrenocortical carcinoma. Oncotarget. 2016;7(29):46734-46749.
Rebecca Neril, Julie Lorton, and Joel Zonszein (2017) NIVOLUMAB-INDUCED ISOLATED ADRENAL INSUFFICIENCY: A CASE REPORT. AACE Clinical Case Reports: Summer 2017, Vol. 3, No. 3, pp. e210-e212.
https://www.mdanderson.org/newsroom/study-shows-possible.h00-159066345.html, 5/9/2016